Abstract
Within this edition of regulatory highlights,we focus on two specific areas.First,a reflection on the status relating to investigation into N-Nitrosamines;and current,growing concerns.Second,we explore the Publication of version 1 of the EMA PRIME Quality toolbox and how this can assist in terms of earlier access to new medicines.
NSTL